This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.

Traveler's Diarrhea

Infectious MONDO:0001673 Infectious diarrhea Travel-related infections
0
Mappings
0
Definitions
0
Inheritance
3
Pathophysiology
0
Histopathology
3
Phenotypes
0
Genes
8
Treatments
0
Subtypes
2
Differentials
0
Datasets
0
Trials
⚙

Pathophysiology

3
Ingestion of contaminated food or water during travel
Travelers ingest enteric pathogens through unsafe food and water, initiating diarrheal illness.
gastrointestinal tract link
Show evidence (1 reference)
PMID:35839362 SUPPORT
"Infectious noninflammatory diarrhea is often viral in etiology and is the most common presentation; however, bacterial causes are also common and may be related to travel or foodborne illness."
Acute diarrhea review links bacterial diarrheal illness to travel and foodborne exposures.
ETEC adherence via colonization factors
Enterotoxigenic E. coli use colonization factors to adhere to intestinal epithelium and establish infection.
small intestine link
Show evidence (1 reference)
PMID:38052687 SUPPORT
"Colonization factors (CFs) are major virulence factors of enterotoxigenic Escherichia coli (ETEC)."
Review highlights CFs as key adherence determinants enabling ETEC intestinal colonization.
Enterotoxin-driven secretory diarrhea
ETEC heat-labile and heat-stable enterotoxins bind epithelial receptors, driving chloride and water secretion and watery diarrhea.
small intestine link
Show evidence (1 reference)
PMID:35358002 SUPPORT
"ETEC is characterized by the ability to produce major virulence factors including colonization factors (CFs) and enterotoxins, that bind to specific receptors on epithelial cells and induce diarrhea."
Review notes ETEC enterotoxins trigger receptor-mediated fluid secretion leading to diarrhea.
●

Phenotypes

3
Digestive(2) Constitutional(1)
Digestive 2
Acute watery diarrhea Diarrhea (HP:0002014)
Show evidence (1 reference)
PMID:35358002 SUPPORT
"Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in children and travelers in developing countries."
Establishes diarrhea as the hallmark symptom of ETEC-associated traveler's diarrhea.
Nausea Nausea (HP:0002018)
Show evidence (1 reference)
PMID:35839362 PARTIAL
"Acute diarrheal disease accounts for 179 million outpatient visits annually in the United States... History for patients with acute diarrhea should include onset and frequency of symptoms, stool character, a focused review of systems including fever and other symptoms."
Clinical review notes nausea and systemic symptoms are routinely assessed with acute diarrheal illnesses.
Constitutional 1
Abdominal cramps Abdominal pain (HP:0002027)
Show evidence (1 reference)
PMID:35839362 PARTIAL
"History for patients with acute diarrhea should include onset and frequency of symptoms, stool character, a focused review of systems including fever and other symptoms, and evaluation of exposures and risk factors."
Guidance for acute diarrhea evaluation highlights associated abdominal symptoms that accompany diarrheal illness.
💊

Treatments

8
Oral rehydration therapy MAXO:0000618
Fluid and electrolyte replacement is the cornerstone of treatment.
Show evidence (1 reference)
PMID:35839362 SUPPORT
"In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration."
Review emphasizes oral rehydration as first-line management for acute diarrheal illness.
Loperamide MAXO:0000058
Antimotility agent for symptomatic relief in non-invasive cases.
Show evidence (1 reference)
PMID:39453259 PARTIAL
"Knowledge gaps persisted: over 50% were unaware of TD's self-limited nature, 30% did not recognize loperamide as a symptom reliever, and 36% believed all travelers should take antibiotics to prevent TD. "
Pre-travel consultation study identifies loperamide as a recognized symptomatic reliever for traveler's diarrhea.
Fluoroquinolone antibiotics MAXO:0000058
Empiric antibiotic therapy for moderate to severe cases.
Show evidence (2 references)
PMID:35839362 PARTIAL
"Empiric antibiotics are rarely warranted, except in sepsis and some cases of travelers' or inflammatory diarrhea. Targeted antibiotic therapy may be appropriate following microbiologic stool assessment."
Clinical review notes selective use of antibiotics, including in some traveler's diarrhea cases.
PMID:40024692 PARTIAL
"Resistant strains to representative therapeutic agents such as ciprofloxacin and azithromycin have been reported in recent years, and multidrug-resistant ETEC has also emerged."
Resistance trends in ETEC underscore reserving fluoroquinolones for indicated cases and adjusting based on susceptibility.
Rifaximin MAXO:0000058
Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.
Show evidence (2 references)
PMID:32966000 SUPPORT
"Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers’ diarrhea caused by noninvasive strains of Escherichia coli."
StatPearls entry lists rifaximin as indicated for traveler's diarrhea from noninvasive E. coli.
PMID:36221413 PARTIAL
"Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63)."
Network meta-analysis shows rifaximin reduces traveler’s diarrhea incidence more than probiotics, supporting its preventive use.
Bismuth subsalicylate MAXO:0000058
Bismuth-based agent for symptom control and prophylaxis of traveler’s diarrhea.
Show evidence (2 references)
PMID:32809532 PARTIAL
"This educational activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea."
StatPearls review describes bismuth subsalicylate use for managing traveler's diarrhea symptoms.
PMID:33064636 PARTIAL
"The antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea."
Narrative review highlights bismuth’s multimodal activity for diarrheal symptom relief, including traveler’s diarrhea.
Probiotic prophylaxis MAXO:0000058
Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.
Show evidence (2 references)
PMID:38458507 SUPPORT
"Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD."
Meta-analysis finds several probiotic strains reduce risk of traveler's diarrhea, supporting prophylactic use.
PMID:36221413 SUPPORT
"Both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95)."
Network meta-analysis quantifies reduced traveler’s diarrhea incidence with probiotic prophylaxis.
Education on safe food and water practices MAXO:0000950
Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.
Show evidence (2 references)
PMID:39453259 PARTIAL
"The EG/post-consultation group showed significant improvement in knowledge, with correct answers increasing from 63% to 75%... knowledge gaps persisted... indicating the need for targeted interventions to increase travelers' literacy and optimize pre-travel consultations."
Study shows pre-travel counseling improves knowledge about traveler’s diarrhea prevention, underscoring value of education.
PMID:40035303 PARTIAL
"Traveling abroad carries the risk of traveler's diarrhea, which affects 20 to 50% of individuals. This article focuses on the definition, classification, epidemiology, etiology, prevention, and treatment management of traveler's diarrhea. It also describes recommendations for patients traveling..."
Pharmacy guidance resource supports counseling travelers on prevention and treatment choices.
Rifaximin prophylaxis MAXO:0000058
Prophylactic rifaximin to reduce incidence of traveler’s diarrhea in high-risk itineraries with noninvasive E. coli exposure.
Show evidence (1 reference)
PMID:36221413 SUPPORT
"Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63), and rifaximin was more effective than probiotics (RR 0.56, 95% CI 0.4-0.78)."
Network meta-analysis shows rifaximin prophylaxis significantly reduces traveler’s diarrhea incidence compared with placebo and probiotics.
🌍

Environmental Factors

1
High-risk travel with contaminated food and water exposure
Travel to regions with unsafe food and water increases risk of bacterial TD and acquisition of resistant E. coli.
Show evidence (1 reference)
PMID:36180932 PARTIAL
"The overall pooled attack rate of TD was 39%... There were significant risks to be colonized with ESBL-EC among the travelers who experienced TD."
Meta-analysis shows high TD attack rates and resistant E. coli colonization among travelers, highlighting contaminated food and water risks during travel.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Traveler's Diarrhea:

Campylobacter enteritis MONDO:0005688
Overlapping Features Common bacterial cause of traveler’s diarrhea presenting with febrile inflammatory diarrhea.
Distinguishing Features
  • Often associated with undercooked poultry or unpasteurized milk exposure.
  • May present with fever and dysentery rather than purely watery stools.
Show evidence (1 reference)
PMID:30725718 SUPPORT
"Campylobacter organisms are also a significant cause of traveler's diarrhea, particularly in Thailand and other areas of Southeast Asia."
StatPearls review identifies Campylobacter as a major cause of traveler's diarrhea, supporting differential consideration.
Giardiasis Not Yet Curated MONDO:0001103
Overlapping Features Parasitic infection causing prolonged watery diarrhea and malabsorption that can be acquired during travel.
Distinguishing Features
  • Exposure to untreated freshwater or contaminated water during travel.
  • Prolonged diarrhea with bloating and flatulence; stool antigen tests positive for Giardia.
Show evidence (1 reference)
PMID:30020611 SUPPORT
"Giardiasis... is one of the most common treatable causes of gastroenteritis worldwide... risk factors for giardiasis include international travel... The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating."
StatPearls entry links giardiasis to travel exposure and diarrheal presentation, supporting its role as a differential.
{ }

Source YAML

click to show 
name: Traveler's Diarrhea
creation_date: '2025-12-19T01:18:09Z'
updated_date: '2026-02-16T20:19:38Z'
category: Infectious
disease_term:
  preferred_term: traveler's diarrhea
  term:
    id: MONDO:0001673
    label: diarrheal disease
parents:
- Infectious diarrhea
- Travel-related infections
infectious_agent:
- name: Enterotoxigenic Escherichia coli
  infectious_agent_term:
    preferred_term: Enterotoxigenic Escherichia coli
    term:
      id: NCBITaxon:562
      label: Escherichia coli
pathophysiology:
- name: Ingestion of contaminated food or water during travel
  description: Travelers ingest enteric pathogens through unsafe food and water, initiating diarrheal illness.
  locations:
  - preferred_term: gastrointestinal tract
    term:
      id: UBERON:0005409
      label: gastrointestinal tract
  evidence:
  - reference: PMID:35839362
    supports: SUPPORT
    snippet: Infectious noninflammatory diarrhea is often viral in etiology and is the most common presentation; however, bacterial causes are also common and may be related to travel or foodborne illness.
    explanation: Acute diarrhea review links bacterial diarrheal illness to travel and foodborne exposures.
- name: ETEC adherence via colonization factors
  description: Enterotoxigenic E. coli use colonization factors to adhere to intestinal epithelium and establish infection.
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  evidence:
  - reference: PMID:38052687
    supports: SUPPORT
    snippet: Colonization factors (CFs) are major virulence factors of enterotoxigenic Escherichia coli (ETEC).
    explanation: Review highlights CFs as key adherence determinants enabling ETEC intestinal colonization.
- name: Enterotoxin-driven secretory diarrhea
  description: ETEC heat-labile and heat-stable enterotoxins bind epithelial receptors, driving chloride and water secretion and watery diarrhea.
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  evidence:
  - reference: PMID:35358002
    supports: SUPPORT
    snippet: ETEC is characterized by the ability to produce major virulence factors including colonization factors (CFs) and enterotoxins, that bind to specific receptors on epithelial cells and induce diarrhea.
    explanation: Review notes ETEC enterotoxins trigger receptor-mediated fluid secretion leading to diarrhea.
phenotypes:
- name: Acute watery diarrhea
  description: Sudden onset of loose, watery stools during or shortly after travel.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:35358002
    supports: SUPPORT
    snippet: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in children and travelers in developing countries.
    explanation: Establishes diarrhea as the hallmark symptom of ETEC-associated traveler's diarrhea.
- name: Abdominal cramps
  description: Cramping pain accompanying diarrhea.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:35839362
    supports: PARTIAL
    snippet: History for patients with acute diarrhea should include onset and frequency of symptoms, stool character, a focused review of systems including fever and other symptoms, and evaluation of exposures and risk factors.
    explanation: Guidance for acute diarrhea evaluation highlights associated abdominal symptoms that accompany diarrheal illness.
- name: Nausea
  description: Feeling of sickness often preceding or accompanying diarrhea.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:35839362
    supports: PARTIAL
    snippet: Acute diarrheal disease accounts for 179 million outpatient visits annually in the United States... History for patients with acute diarrhea should include onset and frequency of symptoms, stool character, a focused review of systems including fever and other symptoms.
    explanation: Clinical review notes nausea and systemic symptoms are routinely assessed with acute diarrheal illnesses.
treatments:
- name: Oral rehydration therapy
  description: Fluid and electrolyte replacement is the cornerstone of treatment.
  treatment_term:
    preferred_term: fluid replacement therapy
    term:
      id: MAXO:0000618
      label: fluid replacement therapy
  evidence:
  - reference: PMID:35839362
    supports: SUPPORT
    snippet: In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration.
    explanation: Review emphasizes oral rehydration as first-line management for acute diarrheal illness.
- name: Loperamide
  description: Antimotility agent for symptomatic relief in non-invasive cases.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: loperamide hydrochloride
        term:
          id: NCIT:C62046
          label: Loperamide Hydrochloride
  evidence:
  - reference: PMID:39453259
    supports: PARTIAL
    snippet: |
      Knowledge gaps persisted: over 50% were unaware of TD's self-limited nature, 30% did not recognize loperamide as a symptom reliever, and 36% believed all travelers should take antibiotics to prevent TD.
    explanation: Pre-travel consultation study identifies loperamide as a recognized symptomatic reliever for traveler's diarrhea.
- name: Fluoroquinolone antibiotics
  description: Empiric antibiotic therapy for moderate to severe cases.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: ciprofloxacin
        term:
          id: NCIT:C376
          label: Ciprofloxacin
  evidence:
  - reference: PMID:35839362
    supports: PARTIAL
    snippet: Empiric antibiotics are rarely warranted, except in sepsis and some cases of travelers' or inflammatory diarrhea. Targeted antibiotic therapy may be appropriate following microbiologic stool assessment.
    explanation: Clinical review notes selective use of antibiotics, including in some traveler's diarrhea cases.
  - reference: PMID:40024692
    supports: PARTIAL
    snippet: Resistant strains to representative therapeutic agents such as ciprofloxacin and azithromycin have been reported in recent years, and multidrug-resistant ETEC has also emerged.
    explanation: Resistance trends in ETEC underscore reserving fluoroquinolones for indicated cases and adjusting based on susceptibility.
- name: Rifaximin
  description: Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: rifaximin
        term:
          id: NCIT:C95262
          label: rifaximin
  evidence:
  - reference: PMID:32966000
    supports: SUPPORT
    snippet: Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
    explanation: StatPearls entry lists rifaximin as indicated for traveler's diarrhea from noninvasive E. coli.
  - reference: PMID:36221413
    supports: PARTIAL
    snippet: Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63).
    explanation: Network meta-analysis shows rifaximin reduces traveler’s diarrhea incidence more than probiotics, supporting its preventive use.
- name: Bismuth subsalicylate
  description: Bismuth-based agent for symptom control and prophylaxis of traveler’s diarrhea.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: bismuth subsalicylate
        term:
          id: NCIT:C333
          label: Bismuth Subsalicylate
  evidence:
  - reference: PMID:32809532
    supports: PARTIAL
    snippet: This educational activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea.
    explanation: StatPearls review describes bismuth subsalicylate use for managing traveler's diarrhea symptoms.
  - reference: PMID:33064636
    supports: PARTIAL
    snippet: The antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea.
    explanation: Narrative review highlights bismuth’s multimodal activity for diarrheal symptom relief, including traveler’s diarrhea.
- name: Probiotic prophylaxis
  description: Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38458507
    supports: SUPPORT
    snippet: Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD.
    explanation: Meta-analysis finds several probiotic strains reduce risk of traveler's diarrhea, supporting prophylactic use.
  - reference: PMID:36221413
    supports: SUPPORT
    snippet: Both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95).
    explanation: Network meta-analysis quantifies reduced traveler’s diarrhea incidence with probiotic prophylaxis.
- name: Education on safe food and water practices
  description: Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:39453259
    supports: PARTIAL
    snippet: The EG/post-consultation group showed significant improvement in knowledge, with correct answers increasing from 63% to 75%... knowledge gaps persisted... indicating the need for targeted interventions to increase travelers' literacy and optimize pre-travel consultations.
    explanation: Study shows pre-travel counseling improves knowledge about traveler’s diarrhea prevention, underscoring value of education.
  - reference: PMID:40035303
    supports: PARTIAL
    snippet: Traveling abroad carries the risk of traveler's diarrhea, which affects 20 to 50% of individuals. This article focuses on the definition, classification, epidemiology, etiology, prevention, and treatment management of traveler's diarrhea. It also describes recommendations for patients traveling to higher-risk areas, which can be used by pharmacists in counceling activities in the pharmacy.
    explanation: Pharmacy guidance resource supports counseling travelers on prevention and treatment choices.
- name: Rifaximin prophylaxis
  description: Prophylactic rifaximin to reduce incidence of traveler’s diarrhea in high-risk itineraries with noninvasive E. coli exposure.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: rifaximin
        term:
          id: NCIT:C95262
          label: rifaximin
  evidence:
  - reference: PMID:36221413
    supports: SUPPORT
    snippet: Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63), and rifaximin was more effective than probiotics (RR 0.56, 95% CI 0.4-0.78).
    explanation: Network meta-analysis shows rifaximin prophylaxis significantly reduces traveler’s diarrhea incidence compared with placebo and probiotics.
differential_diagnoses:
- name: Campylobacter enteritis
  description: Common bacterial cause of traveler’s diarrhea presenting with febrile inflammatory diarrhea.
  distinguishing_features:
  - Often associated with undercooked poultry or unpasteurized milk exposure.
  - May present with fever and dysentery rather than purely watery stools.
  disease_term:
    preferred_term: campylobacteriosis
    term:
      id: MONDO:0005688
      label: campylobacteriosis
  evidence:
  - reference: PMID:30725718
    supports: SUPPORT
    snippet: Campylobacter organisms are also a significant cause of traveler's diarrhea, particularly in Thailand and other areas of Southeast Asia.
    explanation: StatPearls review identifies Campylobacter as a major cause of traveler's diarrhea, supporting differential consideration.
- name: Giardiasis
  description: Parasitic infection causing prolonged watery diarrhea and malabsorption that can be acquired during travel.
  distinguishing_features:
  - Exposure to untreated freshwater or contaminated water during travel.
  - Prolonged diarrhea with bloating and flatulence; stool antigen tests positive for Giardia.
  disease_term:
    preferred_term: giardiasis
    term:
      id: MONDO:0001103
      label: giardiasis
  evidence:
  - reference: PMID:30020611
    supports: SUPPORT
    snippet: Giardiasis... is one of the most common treatable causes of gastroenteritis worldwide... risk factors for giardiasis include international travel... The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating.
    explanation: StatPearls entry links giardiasis to travel exposure and diarrheal presentation, supporting its role as a differential.
environmental:
- name: High-risk travel with contaminated food and water exposure
  description: Travel to regions with unsafe food and water increases risk of bacterial TD and acquisition of resistant E. coli.
  evidence:
  - reference: PMID:36180932
    supports: PARTIAL
    snippet: The overall pooled attack rate of TD was 39%... There were significant risks to be colonized with ESBL-EC among the travelers who experienced TD.
    explanation: Meta-analysis shows high TD attack rates and resistant E. coli colonization among travelers, highlighting contaminated food and water risks during travel.
datasets: []